SCHEMBL11932077

SCHEMBL11932077

CCOC(=O)C(c1ccc(Br)cc1)C1CCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 7/20 0.51
SLC6A2 P23975 5/20 0.51
CYP3A4 P08684 2/20 0.51
TSHR P16473 2/20 0.51
CHRM2 P08172 1/20 0.51
HTR1A P08908 1/20 0.51
ADRA2A P08913 1/20 0.51
CHRM1 P11229 1/20 0.51
DRD1 P21728 1/20 0.51
ADRA1A P35348 1/20 0.51
OPRM1 P35372 1/20 0.51
DRD3 P35462 1/20 0.51
KCNH2 Q12809 1/20 0.51
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
SLC6A4 P31645 3/20 0.50
POLB P06746 1/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28632940 0.85 SLC6A2 (0.67) SLC6A3SLC6A2CYP3A4TSHRCHRM2
SCHEMBL13701464 0.85 SLC6A3 (0.63) SLC6A3SLC6A2SLC6A4
SCHEMBL15919074 0.84 SLC6A2 (0.43) SLC6A3SLC6A2TSHRLMNASLC6A4
SCHEMBL10955574 0.84 SLC6A2 (0.70) SLC6A3SLC6A2CYP3A4TSHRCHRM2
SCHEMBL17892096 0.81 ALDH1A1 (0.48) LMNAMEN1GAAKMT2A
SCHEMBL15919073 0.81 HSD11B1 (0.41) SLC6A3SLC6A2LMNACYP1A2SLC6A4
SCHEMBL11932079 0.81 SLC6A3 (0.54) SLC6A3SLC6A2CYP3A4TSHRCHRM2
SCHEMBL3539654 0.79 SLC6A3 (0.48) SLC6A3SLC6A2CYP3A4TSHRCHRM2
SCHEMBL17145458 0.78 SLC6A3 (0.55) SLC6A3SLC6A2SLC6A4
SCHEMBL17846888 0.78 HTR1E (0.47) LMNAPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649045-B1 SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF BAYER IP GMBH (DE) 2015-05-27 EP disclosed
US-9018258-B2 Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-28 US disclosed
US-9018258-B2 Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-28 US disclosed
US-20120172448-A1 Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-07-05 US disclosed
US-20120172448-A1 Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172448-A1 Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof PC, ACACA, PCCA SLC6A3 3041/4885SLC6A2 2481/4885CYP3A4 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.